Edwards Lifesciences files Form 144 for option exercise

Edwards Lifesciences Corporation submitted a Form 144 notice relating to proposed sales tied to an employee stock option exercise on 05/04/2026, identified as a broker payment for cashless exercise.

Rhea-AI Filing Summary

Edwards Lifesciences Corporation submitted a Form 144 notice relating to proposed sales tied to an employee stock option exercise on 05/04/2026, identified as a broker payment for cashless exercise. The filing also lists prior sales by Daniel J. Lippis on 03/11/2026 (87,004 shares), 04/06/2026 (82,523 shares) and 05/01/2026 (84,585 shares).

Insights

Corporate Governance Analyst

Form 144 notifies the market of planned resales tied to an option exercise and recent sales by an insider.

The filing documents a cashless exercise mechanism where a broker handles share delivery, noted for 05/04/2026. This is procedural: Form 144 provides notice under resale rules rather than signalling a company-level financing.

Prior sale entries by Daniel J. Lippis (87,004; 82,523; 84,585 shares) show recent disposition activity. Subsequent SEC filings or broker reports will confirm actual trades and settlement details.

Key Figures

Employee option exercise date: 05/04/2026 Prior sale by Daniel J. Lippis: 87,004 shares Prior sale by Daniel J. Lippis: 82,523 shares +1 more

4 metrics

Employee option exercise date 05/04/2026 Date tied to broker payment for cashless exercise

Prior sale by Daniel J. Lippis 87,004 shares Sale reported on 03/11/2026

Prior sale by Daniel J. Lippis 82,523 shares Sale reported on 04/06/2026

Prior sale by Daniel J. Lippis 84,585 shares Sale reported on 05/01/2026

Key Terms

Form 144, cashless exercise, broker payment

3 terms

Form 144 regulatory

"submitted a Form 144 notice relating to proposed sales"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

cashless exercise financial

"Broker Payment for Cashless Exercise"

A cashless exercise is a way for an option holder to convert stock options into actual shares without paying the purchase price in cash; instead they immediately give up a portion of the newly issued shares to cover the cost and any withholding taxes. Investors care because this process increases the number of shares available and can slightly dilute existing holdings, while also signaling how insiders or employees are realizing compensation without needing cash — similar to paying for a purchase by handing over part of what you just bought.

broker payment financial

"Broker Payment for Cashless Exercise"

FAQ

What does Edwards Lifesciences' (EW) Form 144 notify?

It notifies the market of proposed resale of shares tied to an employee option exercise on 05/04/2026. The filing describes a broker payment for cashless exercise, which is an administrative resale notice under Rule 144.

Who reported prior sales in the Form 144 for EW?

Daniel J. Lippis is listed with sales on 03/11/2026, 04/06/2026, and 05/01/2026. The reported share amounts are 87,004, 82,523, and 84,585 respectively.

Does the Form 144 say Edwards will receive proceeds from the sale?

The excerpt states the transaction is a broker payment for cashless exercise. It does not state company proceeds; cashless exercises typically involve the broker and holder rather than direct issuer proceeds.

Are the listed prior sales confirmations of completed trades for EW?

The filing lists prior sales dates and share amounts reported by the holder. These entries record dispositions by the reporting person but are not settlement confirmations; broker/trade records provide final settlement details.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/04/2026 - 04:32 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002004380
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Edwards Lifesciences Corp
SEC File Number	001-15525
Address of Issuer	ONE EDWARDS WAY IRVINE CALIFORNIA 92614
Phone	9492502500
Name of Person for Whose Account the Securities are To Be Sold	Lippis Daniel J.
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	1019	85576.00	580800000	05/04/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/04/2026	Employee Stock Option Exercise	EDWARDS LIFESCIENCES CORPORATION			1019	05/04/2026	Broker Payment for Cashless Exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Daniel J. Lippis ONE EDWARDS WAY IRVINE CA 92614	Edwards Lifesciences Corp	03/11/2026	1019	87004.00
Daniel J. Lippis ONE EDWARDS WAY IRVINE CA 92614	Edwards Lifesciences Corp	04/06/2026	1019	82523.00
Daniel J. Lippis ONE EDWARDS WAY IRVINE CA 92614	Edwards Lifesciences Corp	05/01/2026	1019	84585.00

144: Remarks and Signature

Remarks
Date of Notice	05/04/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Daniel J. Lippis
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)